Search the Newsreel

Vraj Iron & Steel Ltd Upgraded to Hold on Improved Valuation and Technicals

Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA

This article provides a financial overview of Zevra Therapeutics, Inc. (FWB:1GDA) on the Frankfurt Stock Exchange, focusing on its price-to-earnings forward metric. It highlights that the market is currently closed with no trades. The content is sourced from FactSet and ICE Data Services.

Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics

Corey M. Watton, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 12,300 shares, valued at $77,859, according to a recent SEC filing. The company's financials show a positive revenue trend with 53.25% growth, a high gross margin of 96.16%, but a …

Vraj Iron Q1 Results FY27: Revenue Rs 193 crore, Net Profit Rs 9 Crore

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Pomerantz LLP is investigating potential securities fraud claims against Zevra Therapeutics, Inc. (ZVRA) following a significant stock price drop. The investigation stems from the European Medicines Agency's negative opinion on Zevra's Marketing Authorization Application for arimoclomol, a drug for Niemann-Pick disease type C. Investors …

Vera Bradley (NASDAQ:VRA) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Vera Bradley (NASDAQ:VRA) shares recently crossed above their 200-day moving average, trading at $3.40 against an average of $3.39, but remained below their 50-day average. Analyst sentiment is cautious with a "Reduce" rating, despite the company beating Q1 earnings expectations with a smaller loss …

Vraj Iron & Steel consolidated net profit rises 51.65% in the June 2026 quarter

Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock

Zevra Therapeutics Director Corey Michael Watton sold 12,300 shares of the company's stock for $138,375.00, reducing his holdings by 87.23% to 1,800 shares. This transaction follows a strong quarterly earnings report where ZVRA exceeded both EPS and revenue estimates. Analysts maintain a "Moderate Buy" …

Vraj Iron and Steel Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Vraj Iron & Steel Q1FY27 consolidated PAT up 52% to ₹115.12 million

Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA

Dimensional Fund Advisors LP significantly increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 259.2% in the first quarter, purchasing an additional 400,336 shares to bring its total holdings to 554,802 shares valued at $5.168 million. Other institutional investors also adjusted their positions in …

Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA

Elevra Lithium (ASX:ELV) Could Be 42% Undervalued After Fresh Operating Results

Vera Bradley Inc (VRA) Stock News Today

This article provides a brief update on Vera Bradley Inc (VRA) stock news. It notes the current stock price and market capitalization, stating that more news, earnings, analyst ratings, and key developments will be available soon. The content indicates that updates are pending.

Vera Bradley Inc (VRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Vera Bradley Inc (VRA), detailing its current earnings forecast score, average price target of $5.50, and analyst ratings. Based on one analyst, the stock holds a "Hold" signal, with an expected revenue of $65.95M for the next …

Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data

Zevra Therapeutics' stock (ZVRA) rose 21.6% following strong Q2 2026 sales of US$39.66 million, driven by high uptake of its Niemann-Pick disease type C therapy, MIPLYFFA. New four-year real-world data for arimoclomol (MIPLYFFA's active ingredient) could be crucial for European regulatory re-examination, potentially reshaping …

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

Zevra Therapeutics (ZVRA) has released new long-term real-world safety and effectiveness data for arimoclomol in adults with Niemann-Pick disease type C, aiming to support its equity story and regulatory efforts in Europe. This data will be crucial as the company seeks a re-examination of …

Zevra Therapeutics (ZVRA) Stock Jumps On Profitability While MIPLYFFA Concentration Lingers

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Zevra Therapeutics, Inc. (ZVRA) securities. This investigation follows a negative opinion from the European Medicines Agency regarding Zevra's drug arimoclomol, which caused a sharp drop in the company's stock …

Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure

FMR LLC and Abigail P. Johnson have disclosed an 8.3% beneficial ownership stake in Zevra Therapeutics (ZVRA) through a Schedule 13G/A filing. FMR LLC has sole voting power over 4,899,562 shares and sole dispositive power over 4,915,717 shares, while Abigail P. Johnson holds sole …

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings

Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside

Zevra Therapeutics, Inc. (ZVRA) has seen its average 12-month price target increase from $24.78 to $25.11, according to estimates from nine analysts. This updated target implies a significant 138% potential upside from the August 5 closing price, with individual forecasts ranging from $20 to …

Vraj Iron & Steel Ltd Downgraded to Sell Amid Valuation and Performance Concerns

ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54

Zevra Therapeutics (NASDAQ: ZVRA) appears significantly undervalued according to GuruFocus' GF Value™, trading at $10.54, which is 54.4% below its intrinsic value estimate of $23.11. Despite strong Q2 2026 revenue growth driven by its product MIPLYFFA, the company's GF Score™ of 64/100 indicates moderate …

Zevra Therapeutics Reports Strong Q2 2026 Earnings with Growth in MIPLYFFA

Zevra Therapeutics announced robust Q2 2026 earnings, reporting $39.7 million in net revenue, a 53% year-over-year increase, largely driven by $30.2 million in U.S. sales of MIPLYFFA. The company also strengthened MIPLYFFA's intellectual property with an Orange Book listing extending to 2041. Despite strong …

Is Zevra Therapeutics Inc (ZVRA) Underperforming After Q2 2026 E

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) reported strong Q2 results, with earnings of $0.25 per share significantly beating the Zacks Consensus Estimate of $0.08, and revenues of $39.66 million surpassing estimates by 22.76%. Despite this positive performance and a 17.4% year-to-date stock increase, the company currently holds …

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

ZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary

Zevra Therapeutics, Inc. reported strong financial results for the quarter ended 2026, with revenue reaching $39.66M and diluted EPS of $0.14, primarily driven by the commercialization of MIPLYFFA. The company highlighted significant revenue growth, successful market penetration for MIPLYFFA, and ongoing progress in its …

Zevra Therapeutics, Inc. GAAP EPS of $0.14 beats by $0.03, revenue of $39.7M beats by $5.82M

* Zevra Therapeutics, Inc. press release [https://seekingalpha.com/pr/20608774-zevra-reports-second-quarter-2026-financial-results-and-corporate-update] (ZVRA [https://seekingalpha.com/symbol/ZVRA]): Q2 GAAP EPS of $0.14 beats by $0.03. * Revenue of $39.7M (+53.4% Y/Y) beats by $5.82M. * * Cash Position: Cash, cash equivalents and investments were $260.2 million as of June 30, 2026. Based …

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics reported strong second-quarter 2026 financial results, with $39.7 million in net revenue, a 53% increase over Q2 2025, primarily driven by MIPLYFFA sales. The company achieved a net income of $8.8 million and maintained a robust cash position of $260.2 million, which …

Elevra Lithium Issues C$65m Convertible Notes to Fund North American Expansion

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Zevra Therapeutics will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, at 11:00 a.m. ET. Members of Zevra’s executive leadership team will deliver the presentation, and management will also be available for one-on-one meetings with registered conference …